ARTICLE | Clinical News
Dinaciclib: Phase IIb/III started
October 29, 2012 7:00 AM UTC
Ligand began a Phase IIb/III trial to evaluate dinaciclib in patients with refractory CLL. The trial start triggers a $2 million milestone payment from partner Merck under a deal to develop dinaciclib...